Neurocrine Biosciences Inc at TD Cowen Novel Mechanisms in Neuropsychiatry Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Philip Nadeau - TD Cowen - Analyst : So Kyle, maybe first on the strategy, could you give us a brief overview of Neurocrine's strategy for developing and commercializing drugs for neurologic and neuropsychiatric conditions? In particular, which indications is Neurocrine most interested in and what types of targets will Neurocrine prioritize?

Question: Philip Nadeau - TD Cowen - Analyst : You obviously have a lot going on internally. What is business -- what is Neurocrine's business development strategy going forward? How would you prioritize -- what do you have going on with the internal innovation versus external innovation opportunities?

Question: Philip Nadeau - TD Cowen - Analyst : You referenced the NBI-'568 data that was recently released. It was a bit controversial among investors. Maybe we'll start with you guys just summarizing what you think were the highlights of the data and what was misunderstood by the investment community.

Question: Philip Nadeau - TD Cowen - Analyst : And given that it was the lowest dose in the trial that worked, how confident are you that you have the right dose? Is it possible that an even lower dose would be better?

Question: Philip Nadeau - TD Cowen - Analyst : And I know you said you don't really understand, but any theories as to why that would be?

Question: Philip Nadeau - TD Cowen - Analyst : We have a call with KOLs this afternoon actually.

Question: Philip Nadeau - TD Cowen - Analyst : As you suggested, that placebo adjusted PANSS score was controversial among investors because it seemed to be a bit lower than what people were expecting. But the effect size was every bit as good as what we've seen before. And that decline from baseline was every bit of what we've seen before. It was just the placebo group. Kyle, as you noted, seemed to have more of a placebo effect than what we've seen in other Phase 2s. As investors try to contextualize the data, what endpoints are particularly important for them to look at? What do you think investors are kind of missing in their focus on the placebo-adjusted PANSS?

Question: Philip Nadeau - TD Cowen - Analyst : It looks like we have about five minutes left. So I did want to touch on some of the other candidates that are moving along: '845 for depression. Can you give us a brief overview of the highlights of the Phase 2 data that were released earlier this year? Where do you see '845 fitting into the treatment paradigm? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 26, 2024 / 3:00PM, NBIX.OQ - Neurocrine Biosciences Inc at TD Cowen Novel Mechanisms in Neuropsychiatry Conference

Question: Philip Nadeau - TD Cowen - Analyst : Have you [said] when you present the Phase 2 data?

Question: Philip Nadeau - TD Cowen - Analyst : Well, with that, I think we're out of time. Thanks, guys, for [giving us time, the portfolio] --